Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
Do patients with Stage III unresectable NSCLC with lepidic features require a different approach to chemo-radiation?
Would your choice of concurrent chemotherapy be impacted by this histologic finding?
Related Questions
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
How do you define an adequate EBUS when staging NSCLC?
What are your top takeaways in Thoracic Cancers from ASCO 2023?
How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
How are you approaching patients with early-stage NSCLC who progress on neoadjuvant chemo-immunotherapy and are no longer surgical candidates?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
How would you approach Grade 2-3 rash due to erlotinib for a patient with metastatic EGFR mutated lung adenocarcinoma that is well controlled for > 5 years and NED by PET?